Recombinant protein diannexin prevents preeclampsia-like symptoms in a pregnant mouse model via reducing the release of microparticles
作者机构：Laboratory MedicinePeking University Third HospitalBeijing100191China Department of Clinical LaboratoryPeking University International HospitalBeijing102206China
出 版 物：《Frontiers of Medicine》 (医学前沿（英文版）)
年 卷 期：2022年第16卷第6期
页 面：919-931页
核心收录：
学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100211[医学-妇产科学] 10[医学]
基 金：supported by Natural Science Foundation of Beijing Municipality(No.7192222) National Natural Science Foundation of China(No.82072352)
主 题：preeclampsia recombinant protein diannexin microparticle NLRP3 inflammasome phosphatidylserin
摘 要：Preeclampsia(PE)is characterized by placenta-mediated pregnancy *** only effective treatment for PE is the delivery of the ***,this treatment may cause preterm birth and neonatal ***,preventing PE is *** mechanism of PE involves abnormal placentation,which leads to the release of anti-angiogenic and inflammatory mediators into maternal *** mediators contribute to systemic vascular dysfunction,inflammatory responses,and excessive thrombin ***(MPs)are reportedly involved in PE by promoting the thromboinflammatory *** study describes a strategy to prevent PE by reducing MP release using the recombinant protein,*** showed that the patients with PE had elevated MP number and procoagulant activity and increased NLRP3 inflammasome ***,diannexin remarkably reduced the release of MPs from activated cells by binding to phosphatidylserine exposed on the surface of activated ***,in vivo results showed that diannexin could prevent PE-like symptoms by decreasing MPs and NLRP3 inflammasome activation in pregnant ***,diannexin effectively inhibited trophoblast cell activation and NLRP3 inflammasome activation in *** findings suggested that diannexin inhibited MP release and might be an effective therapeutic strategy for preventing PE.
维普期刊数据库